Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial.

Cancer Res Treat · 2015 · PMC4614205 · PMID 25672577

Europe PMC DOI

hedged sentence

0.1140

closest p · 2.3× alpha

0.1140

boldest claim

The sentences

did not reach statistical significancep=0.114not close (p > 0.1)

1B ), but the OS did not reach statistical significance (overall p=0.114; pemetrexed-erlotinib vs. erlotinib: hazard ratio [HR], 0.83; and pemetrexed-erlotinib vs. pemetrexed: HR, 0.53) ( Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.